2. Academic Validation
  3. Antitumour imidazotetrazines: past, present… and future?

Antitumour imidazotetrazines: past, present… and future?

  • RSC Chem Biol. 2023 Aug 29;4(10):736-741. doi: 10.1039/d3cb00076a.
Malcolm F G Stevens 1,  Richard T Wheelhouse 2
Affiliations

Affiliations

  • 1 Biodiscovery Institute, School of Pharmacy, University of Nottingham NG7 2RD UK.
  • 2 Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, University of Bradford BD7 1DP UK r.t.wheelhouse@bradford.ac.uk.
PMID: 37799580 DOI: 10.1039/d3cb00076a
Abstract

It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line treatment for glioma but despite the attentions of the inventors and Others, further examples of this intriguing ring system have yet to enter the clinic.

Figures
Products